No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRLD240719C2500
- 2.90
- 0.000.00%
15min DelayClose Jul 12 15:59 ET
2.90High2.90Low
2.90Open2.90Pre Close1 Volume0 Open Interest2.50Strike Price290.00Turnover0.00%IV18.42%PremiumJul 19, 2024Expiry Date2.06Intrinsic Value100Multiplier7DDays to Expiry0.84Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.25Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Prelude Therapeutics (PRLD.US) once surged 28%! Reached clinical trial cooperation and supply agreement with Merck (MRK.US).
Recently, Prelude Therapeutics has reached a clinical trial cooperation and supply agreement with Merck.
Prelude, Merck Strike Clinical Trial Collaboration and Supply Pact
Express News | Prelude Therapeutics- Co, Merck Each Retain All Commercial Rights to Their Respective Compounds, Including as Monotherapy or as Combination Therapies
Express News | Prelude Therapeutics Inc - Expects to Conclude Monotherapy Dose Escalation Mid-2024 and Identify Recommended Phase 2 Dose
Express News | Prelude Therapeutics Inc - Prelude Will Sponsor Clinical Trial and Merck Will Provide Keytruda.
Express News | Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Comments
Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...
$Prelude Therapeutics(PRLD.US$ Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
1
$Prelude Therapeutics(PRLD.US$
Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...
Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...
Wall Street experts reveal the five stocks to buy, five stocks to sell this week
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions(SWKS.US$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions(SWKS.US$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
1
Prelude's CEO, Dr. Kris Vaddi, asserts that the additional funding will boost the clinical development of PRT3789 and progress of the oral program. Further clinical results from PRT3789 and the initiation of their oral program are expected in second half of 2024.
Read more